New Risk • Mar 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.13m free cash flow). Share price has been highly volatile over the past 3 months (45% average weekly change). Revenue has declined by 17% over the past year. Shareholders have been substantially diluted in the past year (433% increase in shares outstanding). Revenue is less than US$1m (kr.5.8m revenue, or US$886k). Market cap is less than US$10m (kr.5.66m market cap, or US$865.9k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). New Risk • Jan 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.13m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue has declined by 17% over the past year. Shareholders have been substantially diluted in the past year (433% increase in shares outstanding). Revenue is less than US$1m (kr.5.8m revenue, or US$909k). Market cap is less than US$10m (kr.14.0m market cap, or US$2.20m). Anuncio • Oct 06
Brain+ A/S Announces CFO Changes Brain+ A/S has appointed Otto Rasmussen, an experienced financial executive, as the Company’s new Chief Financial Officer (CFO). Otto will step into the position with immediate effect, ensuring an effective hand-over from the current CFO, who will transition by end of October 2025. Otto Rasmussen brings extensive experience in financial leadership, strategic life science business planning as well as in international development process optimization and growth strategies. He has experience from both start-ups, small and high-growth companies, private equity backed companies and publicly listed large companies. With a strong and diversified background, Otto will play a key role in supporting Brain+’ continued commercial transition and growth as the Company is establishing a position as a leading provider of innovative digital solutions for better dementia care and therapy. Anuncio • May 30
Brain+ A/S Elects Vishal Shah as New Board Member Brain+ A/S announced that at its AGM held on May 30, 2025, Vishal Shah, who since March 2025 has been acting as board observer and advisor to Brain+ Management, was elected as a new board member. Anuncio • May 17
Brain+ A/S, Annual General Meeting, May 30, 2025 Brain+ A/S, Annual General Meeting, May 30, 2025, at 08:00 Romance Standard Time. Location: svanevej 22, 2, 2400 kobenhavn nv, Denmark Anuncio • May 02
Brain+ A/S Provides Earnings Guidance for 2025 Brain+ A/S provided earnings guidance for 2025. The financial expectations for 2025 include a net loss of DKK 8.0 million to DKK 9.0 million. Anuncio • Apr 16
Brain+ A/S Announces CEO Changes Brain+ A/S (“Brain+” or the “Company”) announces that the Board has appointed the Company’s Chief Commercial Officer (CCO), Devika Wood, as new CEO. Devika will take on her new role with immediate effect. Co-founder and former CEO, Kim Baden-Kristensen, will continue as Strategic Advisor to management. The appointment has been agreed by all parties involved and is a natural part of the Company’s ongoing transition from a mainly research and development led organization to a commercially driven healthtech company. Devika demonstrates strong strategic and commercial expertise with a proven track record of scaling sales for new healthtech ventures, particularly in the UK and US. As the Company’s CCO, she has successfully built awareness and interest for the Ayla dementia care platform in the UK care market resulting in a robust sales pipeline exceeding €600,000+ and recently secured the first UK sale. In the CEO position, Devika will remain focused on commercial business scaling, while current SVP, Partnerships, Fiona Costello will continue to build commercial presence and momentum in the UK. Anuncio • Apr 02
Brain+ A/S has completed a Composite Units Offering in the amount of DKK 7.992837 million. Brain+ A/S has completed a Composite Units Offering in the amount of DKK 7.992837 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 7,080,199
Price\Range: DKK 1.1289
Transaction Features: Rights Offering Anuncio • Mar 11
Vishal Shah Joins Brain+ as Advisor and Board Observer Vishal Shah, a seasoned UK health and care entrepreneur, investor, and non-executive director, joins Brain+ as an Advisor and Board Observer. In this role, Vishal will support the strategic growth and expansion of Ayla, Brain+' cutting-edge dementia care solution, with a primary focus on the UK care home sector. Vishal brings extensive experience in healthcare investment, digital transformation, and operational healthcare in the care sector, making him a valuable addition to the Board of Directors. He is passionate about social care and community engagement, playing a key role in industry leadership through his positions at Care England and Championing Social Care. His commitment to charitable fundraising through adventure further reflects his dedication to supporting communities and improving lives. With the appointment of Vishal, Brain+ strengthens its strategic leadership, ensuring the company remains at the forefront of dementia care innovation, and his expertise in the UK care sector will be instrumental in accelerating Ayla's growth and impact. Vishal joins at a point in time, where Brain+ is making significant commercial strides in the UKcare home market, and next week, the company will provide an update on the status of its sales pipeline along with key performance indicators (KPIs) for 2025. Anuncio • Oct 02
Brain+ A/S Launches Ayla - your CST Assistant into the UK Dementia Market Brain+ A/S recently obtained certification and regulatory registration of Ayla - your CST Assistant as a Medical Device Software in the United Kingdom (UK). Subsequently, the product has now been released for sale. Ayla - your CST Assistant is the only UK certified digital solution to offer scalable, high-quality delivery of Cognitive Stimulation Therapy (CST), which is the only non-pharmacological dementia therapy that is recommended in the UK national health guidelines. Release means that Ayla - your CST Assistant has been made available to dementia therapists and clinicians for download from all relevant distribution platforms, including App Store, Google Play and through the web. Brain+ can now start in earnest to execute on its UK sales plan, targeting the first UK sales contracts to be in place by end 2024 and annual recurring revenue (ARR) of DKK 7-8 million by end 2025 growing to ARR of DKK 25-27 million by end 2027. Brain+ informs to now successfully have launched its first product, Ayla - your CST Assistant, as planned into the UK market. The launch follows the recent UK regulatory registration of Ayla - your CST Assistant as a certified Medical Device Software (UKCA mark). Following its commercial release, Ayla - your CST Assistant is now available to dementia therapists and clinicians for download on iPads, tablets, and other devices through all relevant software distribution platforms, including the App Store, Google Play, and the web to cater for the diverse range of devices and platforms being used in the UK health care system. Specifically, the product can be accessed here: App store: Ayla - your CST Assistant; Google Play: Ayla - your CST Assistant; Web: Ayla - your CST Assistant. With the UK launch of Ayla - your CST Assistant realized according to plan, Brain+ remains confident in its ability to build its market presence and secure the first sales contracts in 2024. The Company retains earlier communicated expectations of reaching annual recurring revenue (ARR) of DKK 7-8 million by end 2025 and ARR of DKK 25-27 million by end 2027. Anuncio • Sep 25
Brain+ A/S Confirms Imminent Commercial Launch of Ayla - Your CST Assistant as a Medical Device in the UK Brain+ A/S has to date in 2024 achieved all planned development and go-to-market milestones and is now ready for launch of Ayla - your CST Assistant in the UK. The product will launch as a UK Class I medical device software, which is a validation of the product's clinical efficacy and safety and key to opening the doors to the dementia care market. Regulatory certification will position Ayla - your CST Assistant as the only medical device software in the UK to deliver Cognitive Stimulation Therapy (CST) - the one non-pharmacological dementia therapy, which is recommended in the country's national health guidelines. Brain+ has established a UK presence and started executing a sales plan that shall lead to the first NHS evaluation track sales contracts in Fourth Quarter 2024. Building from the first contracts and with three additional Ayla product launches in 2025, the Company retains earlier communicated expectations of annual recurring revenue (ARR) of DKK 7-8 million by end 2025 and ARR of DKK 25-27 million by end 2027. Brain+ has advanced significantly in line with its UK focused go-to-market strategy and continuously through Third Quarter 2024 delivered on the remaining outstanding milestones before being ready to launch Ayla - your CST Assistant into the UK dementia market (See Brain+ news release from 23 August 2024: `Fully on track towards market entry and first sales in the United Kingdom in H2 2024' . The UK is the most attractive European market for Brain+' suite of digital dementia care products to deliver and support Cognitive Stimulation Therapy (CST), recently rebranded under the name of Ayla. Ayla - your CST Assistant will be launched in the UK in week 30 September - 4 October 2024 and Brain+ is on track towards reaching the next important milestones of first UK sales in Fourth Quarter 2024 and commercial scaling. Launch of Ayla - your CST Assistant as certified Medical Device secures a strong competitive position Certification in accordance with UK Medical Device Regulations puts Ayla - your CST Assistant in the `medical' category, making the product stand out from non-medical dementia products and giving it a unique position on the UK market. The Medical Device status validates the product's clinical benefits and software quality and is perceived by the UK National Health Service (NHS) as a key stamp of product quality and relevance, thus supporting clinicians' and other key dementia care stakeholders' adoption and willingness to pay for the product. With the certification Brain+ can make medical claims on the clinical efficacy, user relevance and safety of Ayla - your CST Assistant, documenting its product value and supporting higher price and reimbursement levels. Anuncio • Sep 23
Brain+ A/S Informs of Three Product Releases Planned for 2025 and Introduces A Platform Renaming as Part of Its UK Commercialization Brain+ A/S unveils new products planned for 2025 with next step expansions of its dementia offerings towards building the world’s first scalable dementia management platform. Three new software products are planned for release into the UK during 2025 to further scale sales after first product launch of the CST-Assistant by end September 2024: 1) At-home CST support, 2) virtual group CST delivery, and 3) CST Planner. Further, Brain+ is rebranding as part of its UK launch and awareness campaign and reveals in this context a new overarching name for its dementia management platform: Ayla. The CST-Assistant is rebranded as Ayla – your CST Assistant. The full rebranding will be shared over the coming weeks. Brain+ is fully on-track as communicated to release its CST-Assistant on the UK market as a medical device software by end of September 2024. The CST-Assistant is a proprietary software-based solution for highly scalable offerings of Cognitive Stimulation Therapy (CST), a clinically proven interventional therapy for people with dementia. In parallel with ongoing activities to get ready for UK market entry, Brain+ has developed a product roadmap for 2025 and now introduces three new digital dementia products and services to its pipeline for planned release into the UK in 2025. As presented below, the next products will broaden Brain+’ offerings to people with dementia along the patient pathway, thereby opening access to new customer segments and provide upselling opportunities. More specifically, the objective is to offer patient supporting services, which are accessible from home, offer partial virtual delivery of CST programs for further reach and scalability, and provide services to ease logistics and planning related to CST delivery. Anuncio • Sep 05
First Patient Enters in A Clinical Trial to Evaluate Brain+' Next Generation Cognitive Training Technology for Mild Cognitive Impairment In collaboration with Aalborg University Hospital, Brain+ A/S has started a clinical trial of its next generation cognitive training technology, BrainBlossom. BrainBlossom is designed to offer specific cognitive training for people with Mild Cognitive Impairment, often a pre-stage for a dementia diagnosis. The BrainBlossom game has been developed with top scientists as part of a E1.5 million EU grant funded partner project and is a core element in Brain+' pipeline product, CST-MCI. After this new training software has been tested in healthy adults, the clinical trial in 40 people with MCI shall now test its feasibility and impact as a home delivered treatment. If the trial is successful, next steps are a larger clinical trial to generate regulatory data and a partnership, likely with a pharmaceutical company, for commercialization. MCI represents a very large market with an estimated 150-200 million people worldwide living with MCI (3-4 times as many as with dementia), and many new dementia drugs also target MCI (e.g Lecanemab/Lequembi). The Brainblossom technology builds on a validated cognitive training method for MCI and can enable therapeutic delivery at scale and at home A two-armed randomized controlled clinical trial has now started to test the effect and feasibility of BrainBlossom in 40 people with MCI. Trial results are expected to be available in early 2025 and if positive lead to a larger clinical trial to generate regulatory data, and a partnership. Study protocol has been published as a preprint in psyArXiv Brain+ A/S informs that a clinical pilot trial has started to test its next generation cognitive training software, called the Brain+ Brainblossom Game ("BrainBlossom"), in people with Mild Cognitive Impairment. The trial will be conducted Aalborg University hospital, Denmark under the supervision of Neurologist, Professor Jakob Blicher. Brainblossom has been developed under the Company's €1.5 million Eurostars grant funded ActNow project and is a core element in the CST-MCI product in the pipeline. The cognitive training technology is tailored for people with MCI and has been developed based on a validated framework method, which was recently published in Neuroscience & Biobehavioural Reviews within the consortium of partners. The trial is set as a randomised, single-blind controlled study, planned to enroll up to 40 people with MCI. The study has two arms, one with an active condition and one control arm, and study participants will randomly be assigned to one of the two arms, going through a 4-week at home training program. The active condition arm will train memory based on the BrainBlossom solution, while the control arm will look identical, however not include the training element. Patients will be blind to their assigned condition to minimize the impact of expected training effect and patient outcomes. Prior to and after the 4-weeks of training, study participants will go through a comprehensive battery of cognitive tests and questionnaires to identify the extent of the effect of training on their level of cognition. The study will investigate the feasibility of using the BrainBlossom solution as home-based cognitive training for people with MCI and critically explore the impact of the training on commonly experienced cognitive impairments in MCI, namely impairments in short and long-term memories. The study is expected to run through the rest of 2024 and results to be available in early 2025.
MCI is a segment of future interest for Brain+. An estimated 150-200 million people worldwide are living with MCI (3-4 times as many as with dementia), and the condition represents a large unmet clinical need and market opportunity. MCI is a natural part of the Brain+ mission of improving dementia management, addressing the disease earlier in its progression, where the impact of cognitive training has shown to be biggest. If the ongoing clinical trial is successful, next steps for Brain+ with the BrainBlossom training technology will be a larger trial for regulatory data generation, and to enter into a partnership for market-access and commercialization. Such partner could likely be a pharmaceutical company, whose Alzheimer's drug pipeline also targets the MCI stages (eg. Lecanemab/Lequembi), and to which CST is complementary. The Brain+ pipeline product, CST-MCI, will target MCI as a combination of Cognitive Stimulation Therapy and the Brainblossom cognitive training technology for a powerful multi-modal approach to treating cognitive decline in MCI. Anuncio • Sep 03
Brain+ A/S Announces Results from UK Study of the CST Assistant Show Clinical Relevance, Cost-Benefits and Product-Market Fit Brain+ A/S informed of supportive final results from a first UK usability study of the CST-Assistant, which has been conducted in partnership with two local Age UK sites. Both sites have used the product to support the delivery of a full CST (Cognitive Stimulation Therapy) program to a group of people with dementia. The results from the study confirm the clinical relevance and cost-benefit of the CST- Assistant. Also feedback from CST therapists and people with dementia, who participated in the study, was positive, demonstrating early product-market fit of the solution in a UK dementia management context. The results constitute important user and data evidence prior to release of the CST- Assistant into the attractive UK market by end September. Data from the Age UK study confirm that use of the CST- Assistant saves 50% of CST preparation time. Participating CST therapists were satisfied with the CST- Assistant, confirming it makes planning of therapy significantly less difficult and that its content supports different cognitive and physical abilities as well as therapeutic needs of people with dementia. The CST- Assistant was reported to provide for engaging and appropriately challenging CST sessions, making them fun and interactive for all participants. The Age UK study data is early confirmation of product-market fit for the CST- Assistant in the UK. Brain+ A/S informs of supportive final results from a first UK usability study of the CST - which has been conducted in partnership with 2 local Age UK sites in Trafford and in Tameside. The study was initiated in mid-March 2024, and both sites have delivered a full 14 sessions Cognitive Stimulation Therapy (CST) program to a group of People with dementia, using the CST- Assistant. Age UK is the largest charity organization for seniors in the UK and a significant provider of CST to people with dementia. Data and user feedback from the study confirm that the CST- Assistant is clinically relevant, fits well with the UK workflow and provides cost-benefits in the delivery of CST. Results from the study confirms that the CST- Assistant can save 50% of preparation time for CST therapists in connection with the delivery of a full therapy program. CST therapists in the study also reported that use of the CST-Assistant made planning of therapy significantly less difficult compared to not using the product, thus confirming the cost- benefits of the product to facilitate better CST offerings. Users expressed satisfaction with all the content in the CST- Assistant, confirming its suitability for people with dementia spanning different cognitive and physical abilities and needs. This was further confirmed by people with dementia, who participate in the study, as they expressed satisfaction with the technology across all sessions. The CST-Assistant was reported to be fun and interactive for all study participants providing engaging and appropriately challenging activities. The UK study results provide early evidence of the product-market-fit for the CST-Assistant in the UK, showing that the product fits well into the UK dementia care pathway and is considered valuable by both CST therapists and people with dementia receiving CST. The study results thus represent another important Market Access milestone leading up to the planned release of the
product into the attractive UK market by end September and first UK sales before the end of 2024. Anuncio • Aug 27
Brain+ A/S Announces Clinical Evaluation Report of the CST- Assistant Has Now Been Valued for UK Regulatory Compliance Brain+ A/S informed that the Clinical Evaluation Report (CER) of the CST-Assistant has now been validated for UK regulatory compliance by the Company's regulatory advisor in the UK, 8FoldGovernance. Compliance validation of the CER is an important milestone towards certification of the CST-Assistant under the UK Medical Device Regulations (UK MDR). Brain+ expects to release the CST-Assistant as certified as a Class I Medical-Device-Software in the UK by the end of September 2024. The CST-Assistant is the most commercially mature product in Brain+' pipeline of health tech solutions for better dementia management. It is an innovative software-based offering that enables more effective and scalable high-quality delivery of Cognitive Stimulation Therapy (CST), a clinically proven non-drug therapy for people with mild- to moderate dementia. The CER comprises a structured analysis of all available clinical evidence on the CST-Assistant, documenting its safety and performance in clinical use. The CER ties the performance of the CST-Assistant to the clinically documented benefits of the CST method on cognition and behavior for people with mild to moderate dementia, comparable to 6 months delay in cognitive decline. This supports the soft claims for the CST-Assistant as a Medical Device Software to provide benefits equivalent to those reported for traditional CST alone. The CER is a major component of the Technical File required for Medical Device certification of the CST-Assistant. Obtaining Medical Device status for the CST-Assistant will uniquely document the product's clinical relevance for people with dementia, while instilling trust with healthcare systems and payers that the product meets the highest quality and safety standards. The validation and the clinical endorsement of the CER also demonstrates the clinical benefits of the CST-Assistant as well as the cost benefits of the product to healthcare systems and practitioners as a key step towards enabling UK reimbursement. This will in turn open for larger access to the therapy for patients and healthcare systems and strengthen the competitive and commercial position of Brain+. Brain+ will now focus its efforts on finalizing the remaining steps towards UK certification of the CST-Assistant as a Medical-Device-Software. These include UK regulatory compliance of the Company's Quality Management System, upgrade and implementation of design control procedures and compliance with the stringent UK requirements on Data Privacy and Cyber Security and Digital Technology Assessment Criteria (DTAC). Anuncio • Jul 09
The Cst Assistant V2.0 for Cognitive Stimulation Therapy (Cst) Now Released in Denmark Brain+ A/S informs that CST Assistant v2.0 has been released in Denmark. The CST Assistant is a unique software-based solution for the preparation and delivery of Cognitive Stimulation Therapy (CST) to people with dementia. CST is the leading evidence-based non-pharmacological therapy for dementia, recommended by the World Alzheimer's Association and the World Health Organization (WHO) for worldwide implementation. The Danish version 1.0 of the CST Assistant was made available for CST therapists for user testing and feedback in Fourth Quarter 2022, which has led to 6 sales contracts with 4 municipalities. The release of version 2.0 introduces several new features and functional improvements aimed at making the preparation of CST sessions easier and faster, enhancing flexibility and fidelity in conducting the therapy, and offering an overall more personalized experience for CST therapists and people with dementia receiving CST. The CST-Assistant v2.0 will be introduced in the UK as a medical device with medical claims, facilitating better access to reimbursement pathways for medical software solutions. In Denmark, the product has been introduced as a regular health product due to lack of reimbursement options, bypassing the costs of EU medical device certification. Anuncio • Jun 28
Brain+ A/S Announces the Appointment of Devika Rani Wood as Chief Commercial Officer, Effective August 14, 2024 Brain+ A/S announced the appointment of Devika Rani Wood into a new position as Chief Commercial Officer (CCO). Devika will join the BrainPlus team on 14 August 2024, coming from a position as Senior Vice President of New Markets at ORCHA Health LTD. Devika will be based in the UK with the objective of using her extensive UK commercial scale-up and fund-raising experience to build Brain+'s operations and market presence in this key market. She will focus on establishing UK strategic partnerships and customer relations to build and expand market reach and drive business and revenue growth. Devika brings a wealth of experience of how to implement and scale software-based health tech solutions in the UK market from her previous roles; An health tech entrepreneur herself, she was founder and CEO of Vida, a revolutionary elderly care service, which within 12 months delivered £2.1 million in revenue and signed contracts with 8 key local London authorities. Devika successfully exited after 3 years of operations before the company embarked on an M&A strategy. She was awarded Forbes30u30 for Healthcare and Science for her achievements in Vida. In ORCHA Devika has successfully scaled operations into the US and life sciences sector globally, securing multiple six-digit £large contracts. On the health care payer side, she was Director of Digital Health Propositions at AXA Health, UK (95 million customers worldwide), where she launched a virtual diagnostic service as part of their virtual GP (General Practitioner) offering, during the COVID-19 pandemic, resulting in 100% growth year on year in revenue. Devika's extensive background in elderly care focused digital health and strategic market expansion makes her an ideal fit for the Brain+ entry to the UK market. Her deep understanding of the UK health tech landscape will be crucial in driving the adoption Brain+'s dementia management solutions within the National Health Service (NHS) and care sector Her proven ability to implement and scale digital health solutions will support Brain+'s goal of integrating its technologies into the NHS and the care sector, thereby improving care for dementia patients across the UK. Anuncio • Jun 15
Brain+ Announces The CST-Assistant v2.0 is Now Ready for Release in Denmark and on Track for Release in the UK End of Third Quarter of 2024 Brain+ announced that it has completed the development of a significantly upgraded version 2.0 of the CST-Assistant and that the product will be released in the Danish market according to plan later in June 2024. The CST-Assistant is a software-based solution for the standardized, quality ensured and scalable delivery of Cognitive Stimulation Therapy (CST), which is the leading evidence-based non-drug therapy for dementia. The new version will be made available for the company's existing Danish customers, be the basis for potential new municipal contracts and be used in the ongoing CO-PI granted project for the implementation and scaling of the CST-Assistant to support the delivery of CST to people with dementia in Denmark. This marks an important step also towards planned commercial release of the product as a medical device in the United Kingdom (UK) in Third Quarter 2024. Brain+ focuses commercially on the UK market, which represents the currently largest and most attractive market for the CST-Assistant product. CST in its original analogue form as a group-based therapy for people with dementia was invented in the UK where the therapy has the highest penetration and ~6.000 trained CST therapists. CST is also recommended for national implementation by the National Institute of Health and Care Excellence (NICE). The CST-Assistant will be introduced in the UK as a medical device with medical claims, giving it an advantage in the UK health system including enabling better access to the established reimbursement pathways for medical software solutions. In the Danish market the product will initially be introduced as a regular health product to save the costs of EU medical device certification, as it is less important in Denmark, where there are currently no reimbursement options. Product function and impact: The CST-Assistant v2.0 is the culmination of 1 year of development work, based on comprehensive feedback gathered from CST therapist users and CST experts, including a Danish usability study conducted by VIA University College, one of the two accredited CST education institutions in Denmark. The CST-Assistant addresses the primary pain points and needs of therapists delivering CST to people with dementia by providing the world's largest library of expert-validated CST content suited for the wide range of cognitive functioning that is found in people from early mild dementia to late moderate dementia. The therapists can use the product's adaptive functions to instantly tailor a full 7-week, 14 session CST program based on the particular characteristics a CST group participants, including age and physical capabilities - and in full accordance with the CST manual to ensure full clinical compliance. The result is not only that a therapist saves 50% of preparation time on average, but also that the therapy can be delivered in the highest quality in accordance with the CST principles which is crucial for the evidenced clinical effects of the therapy. The technological platform, security requirements, data collection and user functionalities of the CST-Assistant v2.0 is the same across different country versions, but the CST activity content is culturally adapted to each country through a rigorously validated process with leading national CST experts. In the UK version of the product, the content has been co-developed and verified, with the co-author of the original CST manual and leader of UK CST education, Dr. Catrina Craig. Value proposition: The CST-Assistant v2.0 enables health systems, managing the care and treatment of people with dementia, to rapidly and cost-effectively scale their delivery of CST. In the UK CST is the only non-drug therapy for people with dementia, which is recommended for national implementation by NICE. Consulting psychiatrists who are responsible for diagnosing dementia in the UK, are required to offer CST to those diagnosed. In the UK, the benefits of CST is widely recognized, however there is lack of sufficient resources to deliver and scale the therapy as recommended. This can be greatly alleviated by use of the CST-Assistant v2.0, which allows more people to be served with fewer therapists, while ensuring a standardized, high quality delivery of the therapy. Anuncio • May 23
Brain+ A/S Announces Election of Tim Juergens as New Board Member and Chairman Brain+ A/S announced that Tim Juergens was elected as new board member and chairman. Tim has been acting as a board observer and strategic partner to the Company's management since his nomination as new board member and chairman in February 2024. Tim is an experienced healthcare executive with a proven track record also in venture capital and private equity. He is a strong believer in the role and potential of health and therapeutic tech solutions to solve the challenges that are putting global healthcare systems under pressure. Tim has co-founded and manages the healthtech-focused venture capital firm, Seedlink SL and holds several board positions in early-stage healthtech companies including as chairman of the Danish digital health company, Hedia. He is also healthtech advisory board member of Gerresheimer. In addition, Tim brings to Brain+ 20-years of experience from leading country and commercial roles in the big pharma companies, Bayer and Roche, with key competences in General Management, Digital Health Solutions, Medical Devices, Sales Effectiveness, Market Access, Validation, and Market Analysis. Anuncio • Feb 12
Brain+ A/S, Annual General Meeting, May 15, 2024 Brain+ A/S, Annual General Meeting, May 15, 2024. Anuncio • Jan 09
Brain+ A/S Announces CFO Changes Brain+ A/S announced that Hanne Leth Hillman, previous member of the company's Board of Directors and who has served as interim CFO since 1 May 2023, has been appointed as new CFO of the company. Hanne took over as interim CFO to cover for CFO Bertil Stengaard Jessen, who on 1 May 2023 went on a one-year leave of absence. Bertil will now be leaving Brain+ permanently with effect from 29 February 2024 to pursue other career opportunities outside the company. Anuncio • Dec 15
Brain+ A/S Announces Resignation of Anders Härfstrand as Chairman and Member of the Board, Effective from January 31, 2024 Brain+ A/S announced the resignation of Anders Härfstrand as Chairman and member of the board for personal reasons. He will leave the board with effect from 31 January 2024. Anders Härfstrand was elected as new board member at an Extraordinary General Meeting of the company in September 2022 and has since then held the position as Chairman. With his broad experience and insight into the life science industry and his strong business network, Anders has been a valuable figure in the development of the company over the past 1.5 years. Anuncio • Nov 24
Brain+ Nominates to CO-PI Grant of Up to DKK 3.5 Million from Denmark's Business Promotion Board Brain+ A/S announced that Denmark's Business Promotion Board (Erhvervsfremmebestyrelsen) under the Danish Business Authority nominated Brain+ to receive a grant of up to DKK 3.5 million. The grant is intended to support the adoption and scaling of the company's new software product, CST-Therapist Companion, which can support effective and high-quality delivery of Cognitive Stimulation Therapy (CST) for better dementia care. Part of the value offering of Brain+' CST-TC is that it can free up employee resources in the health and elderly sector and as part of the CO-PI grant project, training in the use of CST-TC will be combined with the current CST education of dementia coordinators for a faster uptake of the treatment. In the project, Brain+ collaborate with 7 Danish municipalities, the Danish Alzheimer's Association and the DanAge (AEldresagen) to support the implementation of CST-TC to support the offering of CST in daily dementia care. Brain+ has been nominated as one of ten companies in an initiative by the Danish Business Promotion Board to boost the implementation and scaling of welfare technology, helping to develop Danish companies' position of strength in the area and giving a boost to the welfare sector through better use of new technology. The funding initiative is highly relevant at a time where several relevant technological solutions are ready for implementation into society to help provide for more effective health care. The CO-PI grant is one of three public grant applications, submitted by Brain+ in August 2023, including also an Innobooster grant application for up to DKK 3 million and an EIC (European Innovation Committee) Accelerator application of a combined DKK 60 million in EU grant and equity from the European Central Bank. Recently, Brain was informed that the Innobooster application has not been accepted, and the company is considering whether to reapply. The large EIC grant application for the development and implementation of Brain+' CST-Home Care product was earlier in November submitted for the second stage of evaluation, and a response whether the project has been advanced to the final presentation step is expected by mid-December. Following the CO-PI grant nomination, Brain+ is in ongoing dialogue with the Danish Business Authority to legally validate the project and make any necessary budget adjustments prior to final grant allowance. Final decision will be announced before mid-December. Anuncio • Nov 03
Brain+ A/S Announces Resignation of Betül Susamis Unaran, Member of the Board of Directors, Effective on 30 November Brain+ A/S announced that Betül Susamis Unaran, member of the company's Board of Directors, has informed of her decision to resign from her board position, effective on 30 November. Betül was first elected to the board in September 2022, and her decision to leave her position is a consequence of changes in her other professional commitments. Anuncio • Oct 05
Brain+ A/S Releases New Version of Its Cst-Therapist Companion Dementia Product with Updated User Features Brain+ A/S informed that the company has released an updated version of its digital product, CST-Therapist Companion, which supports dementia coordinators deliver Cognitive Stimulation Therapy (CST) to people with dementia. CST is an evidence based and worldwide recommended non-pharmaceutical therapy that can reduce cognitive decline and improve social skills as well as quality-of-life for people with early Alzheimer's. Brain+' CST-Therapist Companion can reduce preparation time for CST therapists and support a more consistent high-quality delivery of the therapy. CST-Therapist Companion was introduced to the Danish market in November 2022 as a minimum viable product (MVP) version. Based on feedback from users, the company has now made a number of product upgrades and released a new version 1.2 with improved user features and image quality, upgraded interface compatibility and extended licensing management. Brain+' main development activities have been focused on the development of a substantial upgrade of the CST-Therapist Companion product. This upgrade is referred to as product version 2.0, as it represents a considerable increase in terms of the value delivered to dementia therapists offering CST. CST-Therapist Companion v2.0 will include a substantially increased amount of high-quality and specialist validated CST content and features that enables customization of therapy sessions to adapt to the specific characteristics of a given group of people with dementia receiving the therapy. In this regard, the content in CST-Therapist Companion v 2.0 can be adapted to provide the best possible CST support given the level of cognitive ability of the group, which can vary significantly in people with mild to moderate dementia. Other relevant characteristics to consider for the optimal therapy delivery are age, physical abilities, and social preferences. CST-Therapist Companion V2.0 is in the final stage of development and a clinical usability trial of the product is planned to start in Denmark in October 2023. The trial will be conducted in collaboration with the main dementia care and CST specialists in Denmark with participation of six municipalities. Brain+ expects to introduce a commercial version of CST-Therapist Companion v two.0 in H1 2024 following final product adjustments to be based on the outcome of the clinical trial. Anuncio • Sep 08
Brain+ Secures Intellectual Property Rights for CST-Therapist Companion in the Eu and the United Kingdom Brain+ has secured design protection of its most mature digital CST product, CST-Therapist Companion, in the EU and the United Kingdom to safeguard important intellectual property (IP) value of the product and strengthen its competitive position in the company's first target markets. The design and user interface of CST-Therapist Companion, which was introduced to the market by Brain+ last year to support the delivery of Cognitive Stimulation Therapy (CST), has been positively received by CST therapists and coordinators for its simplicity and intuitive usability. The user interface of the product has also been confirmed in usability studies. Since the first introduction of the product in late 2022, Brain+ has worked to improve and upgrade its design and user interface based on input from customers and CST specialists from Denmark, Germany and the UK. At this point, the product has reached a level of market fit that merits protecting its design in the company's main target markets. The design and usability profile of a digital therapeutic can be decisive for the product's clinical use and essential for the healthcare benefits it offers. Protecting these IP elements will make the product harder to replace once users have become familiar with using it and it has been established as part of a medical or therapeutic workflow. The design protections obtained will guarantee Brain+ exclusive rights to the design of CST-Therapist Companion, preventing anyone else from using the same or similar design. The design elements that Brain+ has protected comprise the critical layout and user interface parts of the CST-Therapist Companion product. In addition, some more specific parts of the product that enable an intuitive user interaction are protected. IP protection is extremely important for a growth company and core to attracting pharma partners. For new innovative products like Brain+' suite of CST-based digital therapeutics, the probability of commercial success and the valuation is considerable influenced by whether the essential technology and product elements are legally protected. Design protections and patents form one of several important building blocks to achieving this. Anuncio • Sep 01
Brain+ A/S Provides Earnings Guidance for the Full Year 2023 Brain+ A/S provides earnings guidance for the full year 2023. The company expects to maintain a gross profit for the full year 2023 of DKK 3-4 million. Anuncio • Jul 12
Brain+ A/S Announces Breakthrough Alzheimer's Drug Approval Seen to Renew Dementia Drug Investments and Increase the Potential for Digital Dementia Therapeutics Brain+ A/S announced that the US FDA has granted full approval to Lecanemab, the first ever disease modifying treatment for early Alzheimer's disease, invented by BioArctic AB of Sweden and developed by Eisai and Biogen. Lecanemab has shown to slow brain destruction in Alzheimer's, and after decades of drug failures in the field, experts now see a turning point to renewed investments in dementia drug research and the start of a new era of treatment. Dementia represents an immense unmet need - and there is growing acknowledgement of the role of digital approaches to compliment pharmaceutical treatments in building a more effective dementia ecosystem. Brain+ is a pioneer in the development of evidence-based digital dementia therapeutics to improve cognition in people with early Alzheimer's dementia, and the recent industry news is seen to increase the company's potential to attract co-development partnerships. On 6 July 2023, Lecanemab was granted full approval from the US FDA with an indication to slow disease progression in people with early Alzheimer's Disease. The approval is based on a unanimous recommendation by an FDA advisory panel and follows an accelerated FDA approval of the drug in early January. This means that for the first time ever a disease modifying treatment has become broadly available for people with early Alzheimer's. Lecanemab was invented by Swedish BioArctic AB (Nasdaq Stockholm: BIOA B) and is the result of a development collaboration between Japanese Eisai Co. and Biogen of the US. Huge unmet needs in dementia - and Lecanemab approval expected to spur new era of treatment. WHO estimates that more than 55 million people are living with dementia. This number is estimated to rise to 78 million by 2030 and to 139 million by 2050. Alzheimer's is the most common cause of dementia, accounting for around 60% of cases. The pharmaceutical industry has invested billions of dollars in the development of effective drugs to meet the needs for better treatment of dementia. However, for decades these investments have resulted mainly in failures. With the breakthrough clinical effects shown with Lecanemab and the subsequent approval of this new drug, experts foresee a strong increase in pharma pipeline investments and a whole new class of effective drugs being available forAlzheimer's dementia after a long period of very limited new treatment options. Non-pharmaceutical Cognitive Stimulation Therapy (CST) can enhance the effects of dementia drugs. Renewed interest and investments in the global dementia drug pipeline bode well also for the potential in new combination approaches, combining new clinically meaningful dementia drugs with non-pharmaceutical treatment offerings, in particular digitally delivered therapies. In a systematic Cochrane review from January 2023 based on results from 37 randomized controlled clinical trials, it was concluded that combining non-pharmaceutical Cognitive Stimulation Therapy (CST) with drug treatments provides enhanced cognitive benefits compared to drug treatment alone for people with mild to moderate dementia (2nd systematic Cochrane review (Woods et al., Jan 2023) [1]). Further, clinically relevant improvements were found in communication and social interaction as well as slight benefits in a range of outcomes including Quality of Life, mood and behavior that challenges. Brain+ digital CST products well positioned to complement the Alzheimer's drug pipeline The potential for drug-digital stimulation combination treatments to better manage Alzheimer's dementia represents a major opportunity for Brain+. While there are 140+ potential drug candidates, currently Brain+ is the only known company to focus on digital delivery of Cognitive Stimulation Therapy (CST), which is the non-pharmaceutical therapy with the strongest evidence base worldwide. CST was in 2022 recommended for global implementation by the major policy prescribing NGOs Alzheimer's Disease International and highlighted by WHO as part of the dementia solution. The focus of Brain+ is to deliver digital dementia products, backed by clinical evidence, to attain status as medical devices for prescription and payer reimbursement, like a drug. This places Brain+ in a unique position to bring value to the Alzheimer's space and to developers of new dementia drugs via co-development and/or licensing agreement covering its digital therapies for combination treatments. Growing acknowledgement of the potential in digital solutions from both policy makers and pharma. In their 'Global status report on the public health response to dementia' from 2021, WHO highlights the urgent need to strengthen dementia support at national level, both in terms of care for people with dementia, and in support for the people who provide that care, in both formal and informal settings. During recent years, both the EU and US have established regulatory pathways for digital healthcare products, and large countries like the UK, Germany and France have established reimbursement pathways to further support the development and implementation of digital solutions in healthcare. In response, the pharma industry is starting to realize the attractive potential in combining drugs with digital therapeutics for enhanced treatment benefits. As an example, Eisai's has in its business plan, EWAY2025 announced an intension to build up or collaborate on digital solutions for early diagnosis and early treatment. Subsequently, the Japanese pharma company has announced two collaborations around digital tools in the dementia field: one with Cogstate on the company's digital test for self-assessment of cognitive function (Eisai-doubles-down-cogstate-digital-cognitive-tool-pact) and another broader research collaboration for the development of digital tools for dementia diagnosis and treatment (Eisai launches Gates-backed research collab to develop digital tools for dementia diagnosis, treatment. Board Change • Jul 07
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Director Betul Unaran is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Anuncio • May 27
Brain+ A/S Announces Board Resignation Brain+ A/S on 26th of May at Annual General Meeting approved Lars Terney, has decided to leave the board for work related reasons and Hanne Leth Hillman, who stepped down from the board prior to taking the position as interim CFO, do not stand for re-election. Anuncio • Jan 27
Brain+ A/S Completes Swedish Research Version of Its Dementia Product with the Research Institutes of Sweden and Extends the Collaboration Brain+ A/S announced a Swedish language version of Cognitive Stimulation Therapy has been created in collaboration with the Research Institutes of Sweden (RISE) in the AD-Shield project. This will enable further R&D work with company's Swedish partner research network, including Research Institutes of Sweden (RISE), University of Gothenburg: the Department of Applied IT, Sahlgrenska Academy, and AgeCap. An in-house usability study of the CST product at RISE yielded new recommendations for enhancing User Interaction (UI) design further. Brain+ extended its collaboration with RISE via a key academic partner of Brain+, Associate Professor Rob Lowe, who has moved to RISE, and retains faculty status at the University of Gothenburg. Brain+ has over the last three years entered multiple Alzheimer's focused research and innovation projects with strong Swedish partners, including Research Institutes of Sweden (RISE), University of Gothenburg: Department of Applied IT, Sahlgrenska Academy, AgeCap. Brain+ has several innovation projects with these Swedish partners, including the Eurostars innovation project, AD-shield, funded by the European Union, Vinnova and The Innovation Fund Denmark, and the FORTE-Dementia Scoping project, funded by the Swedish Forskningsrädet för hälsa, arbetsliv och välfärd. Brain+ has worked for 3 years with RISE in the E 1.5 million AD (Alzheimer's Disease) Shield project. During this work, RISE helped develop a Swedish language version of the CST Therapist Companion product and completed an in-house qualitative usability study of the CST product at RISE yielded new recommendations for enhancing User Interaction (UI) design further. Recently, our key collaborator, Rob Lowe, moved to RISE, which further strengthens and extends the collaboration with RISE. Rob retains faculty status at the University of Gothenburg where he continues to work part-time. Anuncio • Jan 12
Brain+ A/S Announces Results from Clinical Study Provide Promising Feasibility Indications for Brain+' CCT Technology for Cognitive Training Brain+ A/S announced that a study conducted by Nottingham University as part of the Brain+ led European Horizon2020 project called Alzheimer's Detect & Prevent has provided promising feasibility indications that Computerized Cognitive Training (CCT) can positively impact the cognitive load in people with Subjective Cognitive Impairments (SCI). In addition to the effect on cognitive load, the CCT training also resulted in improvements in the study participants' performance in a shopping task that mimics real-life shopping. People with SCI have an increased risk of developing dementia and are therefore a highly relevant segment for Brain+. Study design: 86 participants with SCI were recruited and followed through an 8-week intervention with Brain+ 1st generation CCT games. The participants were assigned to either the experimental group (trained with adaptive game versions) or the placebo control group (trained with non-adaptive game versions). The training took place 5 days a week, 20 minutes a day for 8 weeks. All the participants underwent standard cognitive assessments on attention and working memory, brain imaging during a demanding working memory task, which was the Starry Night cognitive test developed by Brain+ and the University of Oxford, and an ecologically valid augmented reality task in a 3D environment at 3 time points, i.e. pre-training, immediately post-training, and at 1-month follow-up. The brain imaging device used was an Artinis Brite, a functional near-infrared spectroscopy headset (fNIRS), which can be likened to a portable fMRI, measuring blood oxygenation changes in areas of the brain. Two Brain+ technologies, CCT and the Starry Night cognitive test, were evaluated in the study: The study evaluated the Brain+ CCT games, which provided the cognitive training element of the intervention, and the Starry Night memory test, which was used to test working memory while participants underwent brain imaging. The 1st Generation CCT games and the Starry Night cognitive test have been developed as part of an EU-Horizon2020 funded innovation project led by Brain+ and with partners University of Oxford, Nottingham University, Aarhus University, Aarhus University Hospital, Alzheimer Europe and the European Brain Council. The project has a budget of €3.5 million and began in November 2018. The main objective is to detect and engage people with cognitive impairment early before Alzheimer's disease manifests to enable prevention efforts. CCT and Starry Night are key components in a pipeline product for people with Mild Cognitive Impairment: The indications of clinical feasibility of the CCT technology are important as the 2nd Generation of CCT games will be a central component in a product Brain+ has in pre-clinical development for people with Mild Cognitive Impairment (MCI). MCI is a pre-stage to dementia and a clinical diagnosis, which is affecting an estimated 150-200 million people worldwide. The MCI targeting product is the third in Brain+'s pipeline, envisioned to combine CCT and the Starry Night cognitive test as an integrated monitoring tool with the Cognitive Stimulation Therapy (CST) technology. The CST technology is the most advanced of Brain+'s platforms as it is the foundation for the CST-Therapist Companion and the CST-Therapist Home Care products. A Danish version of CST-Therapist Companion was introduced commercially in the fourth quarter of 2022, while German and UK versions are expected to be ready for commercialization later in 2023. Anuncio • Dec 29
Brain+ A/S Announces 3-Year Innovation Project with the Danish Life Science Cluster Is Completed with the Brain+ CST-Therapist Companion Product as the Final Output Brain+ A/S announced that A 3-year collaboration project between VIA University College, MedTech Innovation Consortium (MTIC), and Brain+ has been completed. The project aimed to bring digital health solutions to people with dementia, in particular, solutions based on Cognitive Stimulation Therapy, an evidence-based therapy for people with mild to moderate dementia, supported by the World Health Organization. This objective has been fulfilled as a key result is the Brain+ product, CST-Therapist Companion, a digital tool for CST therapists. This product was launched in November 2022 and is now being commercialized by Brain+ in Denmark and will be introduced in Germany in Second Quarter 2023. The project has been funded by the European Union and Denmark's Business Promotion Board (Danmarks Erhvervsfremmestyrelse). In the process the Brain+ team has worked closely for years with the partners, gaining hands-on experience with the use of digitally delivered CST. The first output was an initial Brain+ digital prototype of CST. Based on positive feedback from users and clinicians from the municipalities working with people with dementia, it was decided to proceed with creating a full product with 24 CST sessions. This has been a thorough and iterative process to adapt CST content to a digitally delivered format for use in CST group sessions, with the aim of delivering CST directly in people's homes. In the project, the CST prototype has been in the hands of therapists and people with mild to moderate dementia in several Danish Municipalities, which has yielded invaluable experience that has been shaping the design of Brain+ digital CST, and the CST-Therapist Companion product. Particularly the Municipality of Syddjurs has been a key contributor to the project and their inputs have been very valuable. There were also numerous learnings from both the academic and market near multi-partner collaboration, including some data collected in the final part of the project becoming inaccessible due to procedural errors, resulting in improvements in collaboration processes. All-in-all, the project has been another example of the successful open collaboration approach of Brain+, resulting in a market-ready product that has been co-developed with all the relevant stakeholders in the dementia ecosystem in Denmark. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Vice Chairman Lars Terney is the most experienced director on the board, commencing their role in 2021. Independent Director Hanne Hillman was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Anuncio • Oct 28
Brain+ Announces Board Appointments Brain+ has hired Nahid Zokaei to a new position as Clinical Director, Erik Esmann Poulsen to a new position of Quality Manager, and Lily Anna Mainstone-Cotton as Clinical Research Associate. Nahid will lead the Brain+ clinical pipeline development including academic partnerships. Erik will manage the Brain+ Quality Management Systems and processes, and Lily perform user research to inform R&D. A team expansion to focus efforts on clinical development and market access Since August, Brain+ has expanded its team with three new hires within regulatory, clinical, and user research to support the upcoming launch of its first dementia product, CST-Therapist Companion, and plans to launch two additional Cognitive Stimulation Therapy (CST) products. Clinical Director - Nahid Zokaei, Ph.D. and Sr. Research Fellow Nahid Zokaei is a recognized clinical researcher with deep insights into the cognitive decline in Alzheimer's and dementia. She is the author of many high-profile publications in the field and has a particular focus on the primary clinical targets for Brain+' Digital Therapeutic products (DTx), including memory and attention. More specifically, Nahid's research focuses on the development of selective and sensitive tasks to better phenotype cognitive impairments in neurological disorders such as Alzheimer's and Parkinson's disease and in at-risk individuals. Nahid is currently a Senior Research Fellow and University Research Lecturer at the National Institute for Health Research, Dept. of Experimental Psychology & Oxford Centre for Human Brain Activity at the University of Oxford, United Kingdom, and she is a member of the Brain and Cognition Lab. Quality Manager - Erik Esmann Poulsen, M.Sc. Erik was a senior regulatory specialist at Medidee Services (now Veranex), a leading European regulatory consultancy, and recently Quality Manager at the Danish Digital Health company, Practio. He will manage the Brain+ Quality Management Systems and processes to ensure the quality and safety of Brain+' products in compliance with regulatory and commercial requirements. Clinical Research Associate- Lily Anna Mainstone-Cotton, M.Sc. Cognitive Psychology Lily is a Cognitive Researcher with a strong emphasis on user engagement research and data analytics from digital health companies, Kooth and Okko Health. Lily will be supporting the clinical user needs in R&D, especially around CST for remote use, and analysis of data and real-world evidence from trials and live commercial use. Anuncio • Oct 25
Brain+ Announces Its First Digital Dementia Product, Cognitive Stimulation Therapy (CST)-Therapist Companion Brain+ will open for sales of its first digital4Cognitive Stimulation Therapy (CST)-Therapist Companion, in Denmark on November 1, 2022. This is fully in line with the company's announcement on August 26, 2022, informing that a Danish version of the product would be ready for commercial launch in Fourth Quarter 2022. The confirmed launch follows a period during which the product has been tested by select Danish dementia therapists in a soft launch and thereafter made ready for market launch. The CST-Therapist Companion will be offered via selective B2B contracts in a SaaS (Software as a Service) pricing model to Danish municipalities, who are responsible for the delivery of health care and therapy to people, diagnosed with dementia. The pricing model will be annual subscriptions, which can be done on the level of number of therapists, an entire clinic, or an entire municipality. The next value inflection following this launch will be closing the first sales contracts. CST-Therapist Companion is a new digital product for the delivery of evidence-based Cognitive Stimulation Therapy (CST) to support therapeutic group sessions for people with mild to moderate dementia. CST in its original non-digital form has been demonstrated to treat the cognitive symptoms of dementia and is the globally leading non-pharmaceutical therapy for the disease with use in 35 countries as of today. Brain+'s new digitalized version of CST enables dementia therapists to consistently deliver high-quality CST and at the same time save preparation time. The digital CST version also enables newly trained therapists to get started fast. testimonials from the Danish soft launch of Brain+ CST-Therapist Companion product: Charlotte de Lichtenberg, CST responsible nurse, Rudersdal Municipality: "The first therapy session based on the CST-Therapist Companion was a huge success. Board Change • Sep 07
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Chairman Lars Terney is the most experienced director on the board, commencing their role in 2021. Independent Director Hanne Hillman was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 